Physician profile
Kenneth Williams
NPI 1851480974
$2,349.30
in general payments reported to CMS, 2019-2025
25 companies · $153 in 2025
The $153 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $385 · 2021: $446 · 2022: $476 · 2023: $319 · 2024: $104 · 2025: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $527.80 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $319.72 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $260.13 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $235.88 | 2019-2023 | |
| Janssen Biotech, INC. | $212.26 | 2021-2022 | |
| Abbott Laboratories | $140.20 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Philips North America LLC | $103.51 | 2023 | |
| Janssen Pharmaceuticals, INC | $61.27 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $60.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.77 | 2019 | |
| Abbvie INC. | $48.31 | 2023-2025 | Viberzi, Linzess |
| Lilly USA, LLC | $35.92 | 2019-2020 | |
| Smith+Nephew, INC. | $33.58 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $29.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.12 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acacia Pharma INC | $27.90 | 2022 | |
| Lundbeck LLC | $26.33 | 2025 | Rexulti |
| Melinta Therapeutics, LLC | $25.63 | 2019 | |
| Collegium Pharmaceutical, INC. | $23.25 | 2019 | |
| Amarin Pharma, INC. | $23.01 | 2019 | |
| Pacira Therapeutics, INC. | $21.88 | 2019 | |
| Allergan, INC. | $16.30 | 2019 | |
| Dexcom, INC. | $13.67 | 2025 | Dexcom G6 Transmitter |
| Vyera Pharmaceuticals, LLC | $11.30 | 2019 | |
| Pfizer INC. | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.